Evidence map›Paper›PMID 39548124›Full record

ArticleNPJ breast cancer2024

Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer.

Lauren D Otto-Dobos, Lindsay D Strehle, Brett R Loman, Melina M Seng, Sagar D Sardesai, Nicole O Williams, Margaret E Gatti-Mays, Daniel G Stover, Preeti K Sudheendra, Robert Wesolowski and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lauren D Otto-DobosInstitute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.
Lindsay D StrehleInstitute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-1112-4231
Brett R LomanCenter for Microbial Pathogenesis and Oral and Gastrointestinal Microbiology Research Affinity Group, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-8830-7506
Melina M SengInstitute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.
Sagar D SardesaiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Nicole O WilliamsDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Margaret E Gatti-MaysDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-8914-2897
Daniel G StoverDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-9003-8165
Preeti K SudheendraDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Robert WesolowskiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Rebecca R AndridgeDivision of Biostatistics, The Ohio State University, Columbus, OH, USA.
Michael T BaileyCenter for Microbial Pathogenesis and Oral and Gastrointestinal Microbiology Research Affinity Group, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Leah M PyterInstitute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA. Leah.Pyter@osumc.edu.

Funding

(PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbiditiesR01CA216290 · NCI · OHIO STATE UNIVERSITY · PI PYTER, LEAH M · 2017 to 2021
$2.1M
NCI NIH HHS R01 CA216290
6 · The paper itself

Abstract

Chemotherapy frequently causes debilitating gastrointestinal symptoms, which are inadequately managed by current treatments. Recent research indicates the gut microbiome plays a role in the pathogenesis of these symptoms. The current study aimed to identify pre-chemotherapy microbiome markers that predict gastrointestinal symptom severity after breast cancer chemotherapy. Fecal samples, blood, and gastrointestinal symptom scores were collected from 59 breast cancer patients before, during, and after chemotherapy. Lower pre-chemotherapy microbiome alpha diversity and abundance of specific microbes (e.g., Faecalibacterium) predicted greater chemotherapy-induced gastrointestinal symptoms. Notably, tumor and diet characteristics were associated with lower pre-chemotherapy alpha diversity. Lower baseline alpha diversity also predicted higher chemotherapy-induced microbiome disruption, which was positively associated with diarrhea symptoms. The results indicate certain cancer patients have lower microbiome diversity before chemotherapy, which is predictive of greater chemotherapy-induced gastrointestinal symptoms and a less resilient microbiome. These patients may be strong candidates for pre-chemotherapy microbiome-directed preventative interventions (e.g., diet change).

Identifiers

PMID39548124
PMCPMC11568184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.